HydroGraph Inc. partners with Hawkeye Bio on medical testing applications
August 18, 2025
by CM Staff
Under a new commercialization agreement, Ease Healthcare will market the LEAP (Lung Enzyme Activity Profile) early detection test that incorporates HydroGraph’s patented fractal graphene.
VANCOUVER — HydroGraph Inc., a manufacturer of ultra-pure graphene, announced its role in a new lung cancer screening product underpinning a collaboration between Hawkeye Bio (Torrance, California) and Ease Healthcare (Pasadena, California). Under a new commercialization agreement, Ease Healthcare will market the LEAP (Lung Enzyme Activity Profile) early detection test that incorporates HydroGraph’s patented fractal graphene.
LEAP is a non-invasive, radiation-free, and sensitive blood test reportedly designed to detect early signs of lung cancer, even in asymptomatic patients, and across all subtypes. Initially targeting high-risk populations including older smokers, military personnel, firefighters, and first responders, HydroGraph Inc. says that the test has demonstrated a 99.8% negative predictive value, significantly improving early detection outcomes.
In a press release, HydroGraph said its “explosion synthesis technology produces ultra-pure graphene that forms the foundation of Hawkeye Bio’s patented biosensor which measures enzymatic activity associated with inflammatory disease” — a key biomarker in early-stage cancer detection.
“This partnership underscores the medical potential of high-purity graphene,” said Kjirstin Breure, President and CEO of HydroGraph. “Our ability to deliver graphene at scale supports groundbreaking diagnostics like Hawkeye’s biosensors and Ease’s LEAP test, ultimately saving lives through earlier detection and intervention.”
“In addition to tobacco use, exposure to environmental pollutants and workplace carcinogens can significantly increase one’s risk of getting lung cancer,” said André de Fusco, CEO and co-founder of Hawkeye Bio. “Improved compliance with lung cancer screening guidelines may lead to earlier detection and improve radiotherapy and surgical outcomes. Our nano-scale graphene biosensors allow Ease Healthcare to bring LEAP testing to primary care physicians as a cost-effective diagnostic solution they can use in routine medical visits.”
HydroGraph Inc. says that Hawkeye Bio is the first company to manufacture nanoscale graphene biosensors for clinical cancer detection and holds patents across the U.S., UK, EU, Japan, Korea, Hong Kong, and Taiwan.
